• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Exact Sciences Announces First-Quarter 2025 Results

    5/1/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email

    First quarter highlights

    • Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million
    • Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively
    • Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test
    • Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024.

    "Our strong first quarter results pave the way for 2025 to mark our most transformative year yet," said Kevin Conroy, chairman and CEO. "The Exact Sciences team just launched two innovative tests: Cologuard Plus, our next-generation colon cancer screening test, and Oncodetect, our molecular residual disease test. These additions expand our portfolio and move us closer to our goal of helping to eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment. With growing momentum in our commercial organization and improved profitability, we raised our full-year outlook and continue to build a foundation for sustained, long-term growth."

    First-quarter 2025 financial results

    For the three-month period ended March 31, 2025, as compared to the same period of 2024 (where applicable):

    • Total revenue was $707 million, an increase of 11% on a reported and core revenue basis
    • Screening revenue was $540 million, an increase of 14%
    • Precision Oncology revenue was $167 million, an increase of 2%, or 4% on a core revenue basis
    • Gross margin was 71%, and adjusted gross margin was 74%, an increase of nearly 50 basis points
    • Net loss was $101 million, or $0.54 per share, an improvement of $9 million and $0.06 per share, respectively
    • Adjusted EBITDA was $63 million, an increase of $24 million or 61%, and adjusted EBITDA margin was 9%, an increase of 280 basis points
    • Operating cash flow was $31 million and free cash flow was break-even, increases of $113 million and $120 million, respectively
    • Cash, cash equivalents, and marketable securities were $786 million at the end of the quarter

    Screening primarily includes laboratory service revenue from Cologuard tests and PreventionGenetics. Precision Oncology includes laboratory service revenue from global Oncotype DX® and therapy selection tests.

    Platform and pipeline advancements

    In the first quarter, Exact Sciences launched the Cologuard Plus test, the company's next-generation colon cancer screening test. The Cologuard Plus test detects cancers and precancerous polyps with even greater sensitivity than the Cologuard test while reducing false positives by nearly 40 percent. This advancement enhances the Company's screening capabilities and reinforces its commitment to delivering high-quality, non-invasive options for patients. The Company launched the Cologuard Plus test with Medicare coverage and secured HEDIS guideline inclusion in March 2025.

    In April, Exact Sciences launched the Oncodetect test, its molecular residual disease and recurrence monitoring test. Oncodetect identifies residual disease up to two years earlier than imaging, the current standard of care. The Company expects to obtain Medicare reimbursement in colon cancer in the second quarter of 2025.

    Exact Sciences is on track for the launch of CancerguardTM EX, a laboratory-developed multi-cancer screening test, in the second half of 2025. Additionally, Exact Sciences is on track to share results from the pivotal BLUE-C study supporting its colon cancer blood test in mid-summer of 2025. The Company will bring both tests to patients through its large commercial organization and unique ExactNexusTM technology platform.

    2025 outlook

    The Company has updated its full-year 2025 revenue and adjusted EBITDA guidance:

     

    Prior guidance

     

    May 1 update

     

    Change at midpoint

     

    Y/Y growth rate

    Total revenue

    $3.025 - $3.085 billion

     

    $3.070 - $3.120 billion

     

    $40.0 million

     

    12%

    Screening

    $2.350 - $2.390 billion

     

    $2.390 - $2.425 billion

     

    $37.5 million

     

    14%

    Precision Oncology

    $675 - $695 million

     

    $680 - $695 million

     

    $2.5 million

     

    5%

    Adjusted EBITDA

    $410 - $440 million

     

    $425 - $455 million

     

    $15.0 million

     

    36%

    First-quarter 2025 conference call & webcast

    Company management will host a conference call and webcast on Thursday, May 1, 2025, at 5 p.m. ET to discuss first-quarter 2025 results. The webcast will be available at exactsciences.com. Domestic callers should dial 888-330-2384 and international callers should dial +1-240-789-2701. The access code for both domestic and international callers is 4437608. A replay of the webcast will be available at exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

    Non-GAAP disclosure

    In addition to the Company's financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents the following non-GAAP measures:

    Core revenue — Core revenue is calculated to adjust for recent acquisitions and divestitures and foreign currency exchange rate fluctuations. Revenue from recent acquisitions is adjusted for the 12 months following acquisition when the periods are not comparable. To exclude the impact of change in foreign currency exchange rates from the prior period under comparison, the Company converts the current period non-U.S. dollar denominated revenue using the prior year comparative period exchange rates.

    Adjusted EBITDA and adjusted EBITDA margin — The Company defines adjusted EBITDA as net loss adjusted for interest expense, income tax expense or benefit, depreciation expense, amortization of acquired intangible assets, investment income or loss, and certain other items which include significant non-cash items and other charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. These items are discussed in more detail below in the tables captioned "U.S. GAAP to Non-GAAP Reconciliation". Adjusted EBITDA margin is calculated as adjusted EBITDA divided by total revenue.

    Adjusted gross profit, adjusted research and development expenses, adjusted sales and marketing expenses, adjusted general and administrative expenses, adjusted loss from operations, adjusted net loss before tax, adjusted income tax expense (benefit), adjusted net loss, and adjusted earnings per share — The Company refers to various "adjusted" amounts or measures on an "adjusted" basis, which exclude the impact of amortization of intangible assets and certain charges or benefits resulting from transactions or events that are highly variable, significant in size, and that we do not believe are indicative of ongoing or future business operations. These items are described in more detail below in the tables captioned "U.S. GAAP to Non-GAAP Reconciliation". The Company also presents certain of these adjusted measures as a percentage of revenue including adjusted gross margin.

    Free cash flow — The Company defines free cash flow as net cash used in or provided by operating activities, reduced by purchases of property, plant and equipment. Management uses free cash flow as a liquidity measure.

    Management believes that presentation of non-GAAP financial measures provides supplemental information useful to investors in understanding our underlying operating results and trends. Non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability of the Company's operating results across reporting periods. Management uses this non-GAAP financial information to establish budgets, manage the Company's business, and set incentive and compensation arrangements. Free cash flow provides useful information to management and investors since it measures our ability to generate cash from business operations. Non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. For example, adjusted gross margin and adjusted gross profit exclude the amortization of acquired intangible assets although such measures include the revenue associated with the acquisitions. Additionally, adjusted EBITDA and other adjusted operating result metrics exclude a number of expense items that are included in net loss. As a result, positive adjusted EBITDA, adjusted operating income, or adjusted earnings per share may be achieved while a significant net loss persists. For more information on these non-GAAP financial measures, see the tables captioned "U.S. GAAP to Non-GAAP Reconciliation." The Company presents certain forward-looking statements about the Company's future financial performance that include non-GAAP measures. These non-GAAP measures include adjustments like stock-based compensation, acquisition and integration costs including gains and losses on contingent consideration, and other significant charges or gains that are difficult to predict for future periods because the nature of the adjustments pertain to events that have not yet occurred. Additionally, management does not forecast many of the excluded items for internal use. Information reconciling forward-looking non-GAAP measures to U.S. GAAP measures is therefore not available without unreasonable effort and is not provided. The occurrence, timing, and amount of any of the items excluded from GAAP to calculate non-GAAP could significantly impact the Company's GAAP results.

    About the Cologuard® and Cologuard Plus™ tests:

    Developed in collaboration with Mayo Clinic, the Cologuard and Cologuard Plus tests are non-invasive colorectal cancer (CRC) screening options for the 110 million U.S. adults ages 45 or older who are at average risk for the disease.

    The Cologuard test revolutionized CRC screening by detecting specific DNA markers and blood associated with cancer and precancer in stool, allowing patients to use the test at home without special preparation or time off. It is covered by Medicare and included in national screening guidelines from both the American Cancer Society (2018) and the U.S. Preventive Services Task Force (2021). Since its launch in 2014, the Cologuard test has been used to screen for CRC 19 million times.

    Building on this success, the FDA-approved Cologuard Plus test raises the performance bar even further and features novel biomarkers, improved laboratory processes, and enhanced sample stability. The Cologuard Plus test is expected to reduce false positives by nearly 40%, to help minimize unnecessary follow-up colonoscopies. Both tests demonstrate Exact Sciences' commitment to improving CRC screening access and outcomes. Exact Sciences launched the Cologuard Plus test with Medicare coverage and guideline inclusion in the first quarter of 2025.

    About the Oncodetect™ test

    Molecular residual disease refers to the presence of tumor-specific DNA in the body. These fragments of genetic information, known as circulating tumor DNA (ctDNA), are shed into the bloodstream by tumors, and their presence may indicate that cancer is present. Exact Sciences' MRD offering leverages our in-house capabilities in whole exome sequencing to offer a tumor-informed MRD test for a personalized approach to detecting and monitoring residual cancer in patients with solid tumors. By identifying somatic genomic alterations in tumor DNA and detecting a subset in ctDNA from blood, the Oncodetect test enables the detection of ctDNA before, during, and after treatment. This critical information can guide therapy decisions and monitor for cancer recurrence.

    About the Cancerguard™ test

    The Cancerguard test, currently in development, is designed to detect multiple cancers in their earliest stages from a single blood draw. Building upon decades of research, Exact Sciences intends to harness the additive sensitivity of multiple biomarker classes to detect more cancers in earlier stages. The Cancerguard test will utilize a streamlined and standardized imaging-based diagnostic pathway, which may result in fewer follow-up procedures. The test is being developed to provide high specificity to help minimize false positives while detecting multiple cancers, including those with the biggest toll on human health. These features describe current development goals. The Cancerguard test has not been cleared or approved by the U.S. Food and Drug Administration or any other national regulatory authority. To learn more, visit http://www.exactsciences.com/cancerguard.

    About Exact Sciences' Precision Oncology portfolio

    Exact Sciences' Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX test is recognized as the standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra® test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine, by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com.

    About PreventionGenetics

    Founded in 2004 and located in Marshfield, Wisconsin, PreventionGenetics is a CLIA and ISO 15189:2012 accredited laboratory. PreventionGenetics delivers clinical genetic testing of the highest quality at fair prices with exemplary service to people around the world. PreventionGenetics has 25 PhD geneticists on staff and provides tests for nearly all clinically relevant genes including the powerful and comprehensive germline whole genome sequencing test, PGnome® and whole exome sequencing test, PGxome®. PreventionGenetics was acquired by Exact Sciences in December 2021.

    About Exact Sciences Corp.

    A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard and Oncotype DX tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

    Forward-Looking Statements

    This news release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development or launching of new or improved products and services and their impact on patients; insurance reimbursement potential; our strategies, commercialization efforts, positioning, competition, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts.

    Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully develop and commercialize new products and services and assess potential market opportunities; our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our reliance upon certain suppliers; our ability to retain and hire key personnel; approval and maintenance of adequate reimbursement rates for our products and services within and outside of the U.S.; the amount and nature of competition for our products and services; the effects of any judicial, executive or legislative action affecting us or the healthcare system; changes in government policies, laws, regulations, and staffing; recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or our products and services; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; our ability to protect and enforce our intellectual property; our success establishing and maintaining collaborative, licensing, and supplier arrangements; the results of our validation studies and clinical trials, including the risks that the results of future studies and trials may differ materially from the results of previously completed studies and trials; our ability to manage an international business and our expectations regarding our international expansion and opportunities; the potential effects of changing macroeconomic conditions and geopolitical conflict; the possibility that the anticipated benefits from our business acquisitions will not be realized in full or at all or may take longer to realize than expected; the outcome of any potential litigation or legal proceeding; and our ability to raise the capital necessary to support our operations or meet our payment obligations under our indebtedness. The risks included above are not exhaustive. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    EXACT SCIENCES CORPORATION

    Selected Unaudited Financial Information

    Condensed Consolidated Statements of Operations

    (Amounts in thousands, except per share data)

     

    ​

    Three Months Ended

    March 31,

    ​

    2025

     

    2024

    Revenue

    $

    706,785

     

     

    $

    637,524

     

     

     

     

     

    Cost of sales

     

    206,238

     

     

     

    191,201

     

    Gross profit

     

    500,547

     

     

     

    446,323

     

     

     

     

     

    Operating expenses

     

     

     

    Research and development

     

    105,310

     

     

     

    110,869

     

    Sales and marketing

     

    264,310

     

     

     

    217,780

     

    General and administrative

     

    220,686

     

     

     

    219,652

     

    Impairment of long-lived and indefinite-lived assets

     

    6,251

     

     

     

    4,446

     

    Total operating expenses

     

    596,557

     

     

     

    552,747

     

     

     

     

     

    Other operating loss

     

    —

     

     

     

    (268

    )

    Loss from operations

     

    (96,010

    )

     

     

    (106,692

    )

     

     

     

     

    Other income (expense)

     

     

     

    Investment income, net

     

    4,997

     

     

     

    6,213

     

    Interest expense

     

    (9,978

    )

     

     

    (7,943

    )

    Total other income (expense)

     

    (4,981

    )

     

     

    (1,730

    )

     

     

     

     

    Net loss before tax

     

    (100,991

    )

     

     

    (108,422

    )

     

     

     

     

    Income tax expense

     

    (224

    )

     

     

    (1,806

    )

     

     

     

     

    Net loss

    $

    (101,215

    )

     

    $

    (110,228

    )

     

     

     

     

    Net loss per share—basic and diluted

    $

    (0.54

    )

     

    $

    (0.60

    )

     

     

     

     

    Weighted average common shares outstanding—basic and diluted

     

    186,813

     

     

     

    182,350

     

    EXACT SCIENCES CORPORATION

    Selected Unaudited Financial Information

    Condensed Consolidated Balance Sheets

    (Amounts in thousands)

     

     

    March 31,

    2025

     

    December 31,

    2024

    Assets

     

     

     

    Cash and cash equivalents

    $

    347,127

     

    $

    600,889

    Marketable securities

     

    439,048

     

     

    437,137

    Accounts receivable, net

     

    279,800

     

     

    248,968

    Inventory

     

    176,574

     

     

    162,383

    Prepaid expenses and other current assets

     

    127,792

     

     

    122,046

    Property, plant and equipment, net

     

    697,907

     

     

    693,673

    Operating lease right-of-use assets

     

    126,659

     

     

    116,952

    Goodwill

     

    2,367,111

     

     

    2,366,676

    Intangible assets, net

     

    988,873

     

     

    1,009,693

    Other long-term assets, net

     

    160,182

     

     

    169,722

    Total assets

    $

    5,711,073

     

    $

    5,928,139

     

     

     

     

    Liabilities and stockholders' equity

     

     

     

    Convertible notes, net, current portion

    $

    —

     

    $

    249,153

    Current liabilities

     

    502,465

     

     

    483,034

    Convertible notes, net, less current portion

     

    2,322,574

     

     

    2,321,067

    Other long-term liabilities

     

    320,225

     

     

    315,503

    Operating lease liabilities, less current portion

     

    168,902

     

     

    157,133

    Total stockholders' equity

     

    2,396,907

     

     

    2,402,249

    Total liabilities and stockholders' equity

    $

    5,711,073

     

    $

    5,928,139

    EXACT SCIENCES CORPORATION

    U.S. GAAP to Non-GAAP Reconciliation

    Core Revenue

    (Unaudited)

    (Amounts in thousands)

     

     

     

    GAAP

     

     

     

     

     

     

     

     

    Three Months Ended March 31,

     

     

     

     

     

     

     

     

    2025

     

    2024

     

    % Change

     

     

     

     

     

     

    Screening

     

    $

    540,007

     

     

    $

    474,798

     

     

    14

    %

     

     

     

     

     

     

    Precision Oncology

     

     

    166,778

     

     

     

    162,726

     

     

    2

    %

     

     

     

     

     

     

    Total

     

    $

    706,785

     

     

    $

    637,524

     

     

    11

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Non-GAAP

     

     

     

     

     

     

     

     

    Three Months Ended March 31,

     

     

     

     

    2025 (1)

     

    2024 (1)

     

    % Change

     

    Foreign

    Currency

    Impact (2)

     

    Core

    Revenue (3)

     

    % Change (3)

    Screening

     

    $

    540,007

     

     

    $

    474,798

     

     

    14

    %

     

    $

    —

     

    $

    540,007

     

    14

    %

    Precision Oncology

     

     

    166,778

     

     

     

    160,659

     

     

    4

    %

     

     

    540

     

     

    167,318

     

    4

    %

    Total

     

    $

    706,785

     

     

    $

    635,457

     

     

    11

    %

     

    $

    540

     

    $

    707,325

     

    11

    %

    ________________

    (1) Excludes revenue from the divested Oncotype DX Genomic Prostate Score test.

     

    (2) Foreign currency impact is calculating the change in current period non-U.S. dollar denominated revenue using the prior year comparative period exchange rates.

     

    (3) Excludes revenue from the divested Oncotype DX Genomic Prostate Score test and the impact of foreign currency exchange rate fluctuations.

    EXACT SCIENCES CORPORATION

    U.S. GAAP to Non-GAAP Reconciliation

    Adjusted EBITDA

    (Unaudited)

    (Amounts in thousands)

     

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

    2024

    Net loss

     

    $

    (101,215

    )

     

    $

    (110,228

    )

    Interest expense

     

     

    9,978

     

     

     

    7,943

     

    Income tax expense

     

     

    224

     

     

     

    1,806

     

    Investment income

     

     

    (4,997

    )

     

     

    (6,213

    )

    Depreciation and amortization

     

     

    54,061

     

     

     

    53,943

     

    Stock-based compensation (1)

     

     

    65,880

     

     

     

    73,538

     

    Acquisition and integration costs (2)

     

     

    8,287

     

     

     

    10,765

     

    Impairment of long-lived and indefinite-lived assets (3)

     

     

    6,251

     

     

     

    4,446

     

    Loss on sale of asset (4)

     

     

    —

     

     

     

    268

     

    Restructuring and business transformation (5)

     

     

    24,788

     

     

     

    2,936

     

    Adjusted EBITDA

     

    $

    63,257

     

     

    $

    39,204

     

    Adjusted EBITDA margin

     

     

    9

    %

     

     

    6

    %

    ________________

    Refer below the Reconciliations of U.S. GAAP to Non-GAAP Measures section for endnote descriptions.

    EXACT SCIENCES CORPORATION

    U.S. GAAP to Non-GAAP Reconciliation

    U.S. GAAP to Non-GAAP Measures

    (Unaudited)

    (Amounts in thousands)

     

     

     

    Three Months Ended March 31, 2025

     

     

    Gross

    Profit

     

    Research &

    Development

    Expenses

     

    Sales &

    Marketing

    Expenses

     

    General &

    Administrative

    Expenses

     

    Loss

    from

    Operations

     

    Net Loss

    Before

    Tax

     

    Income

    Tax

    Benefit

    (Expense)

     

    Net Loss

     

    Net Loss

    Per

    Share

    Reported

     

    $

    500,547

     

     

    $

    105,310

     

     

    $

    264,310

     

     

    $

    220,686

     

     

    $

    (96,010

    )

     

    $

    (100,991

    )

     

    $

    (224

    )

     

    $

    (101,215

    )

     

    $

    (0.54

    )

    Reported percent of revenue

     

     

    71

    %

     

     

    15

    %

     

     

    37

    %

     

     

    31

    %

     

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

     

    20,768

     

     

     

    (1,383

    )

     

     

    (1,924

    )

     

     

    (26

    )

     

     

    24,101

     

     

     

    24,101

     

     

     

    (1,070

    )

     

     

    23,031

     

     

     

    0.12

     

    Acquisition and integration costs (2)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (8,287

    )

     

     

    8,287

     

     

     

    8,287

     

     

     

    (20

    )

     

     

    8,267

     

     

     

    0.04

     

    Impairment of long-lived and indefinite-lived assets (3)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    6,251

     

     

     

    6,251

     

     

     

    —

     

     

     

    6,251

     

     

     

    0.03

     

    Restructuring and business transformation (5)

     

     

    342

     

     

     

    (428

    )

     

     

    (5,931

    )

     

     

    (18,087

    )

     

     

    24,788

     

     

     

    24,788

     

     

     

    (61

    )

     

     

    24,727

     

     

     

    0.13

     

    Adjusted (non-GAAP)

     

    $

    521,657

     

     

    $

    103,499

     

     

    $

    256,455

     

     

    $

    194,286

     

     

    $

    (32,583

    )

     

    $

    (37,564

    )

     

    $

    (1,375

    )

     

    $

    (38,939

    )

     

    $

    (0.21

    )

    Adjusted percent of revenue (non-GAAP)

     

     

    74

    %

     

     

    15

    %

     

     

    36

    %

     

     

    27

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended March 31, 2024

     

     

    Gross

    Profit

     

    Research &

    Development

    Expenses

     

    Sales &

    Marketing

    Expenses

     

    General &

    Administrative

    Expenses

     

    Loss

    from

    Operations

     

    Net Loss

    Before

    Tax

     

    Income

    Tax

    Benefit

    (Expense)

     

    Net Loss

     

    Net Loss

    Per

    Share

    Reported

     

    $

    446,323

     

     

    $

    110,869

     

     

    $

    217,780

     

     

    $

    219,652

     

     

    $

    (106,692

    )

     

    $

    (108,422

    )

     

    $

    (1,806

    )

     

    $

    (110,228

    )

     

    $

    (0.60

    )

    Reported percent of revenue

     

     

    70

    %

     

     

    17

    %

     

     

    34

    %

     

     

    34

    %

     

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

     

    21,100

     

     

     

    (261

    )

     

     

    (1,924

    )

     

     

    (26

    )

     

     

    23,311

     

     

     

    23,311

     

     

     

    675

     

     

     

    23,986

     

     

     

    0.13

     

    Acquisition and integration costs (2)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (10,765

    )

     

     

    10,765

     

     

     

    10,765

     

     

     

    (25

    )

     

     

    10,740

     

     

     

    0.06

     

    Impairment of long-lived and indefinite-lived assets (3)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    4,446

     

     

     

    4,446

     

     

     

    —

     

     

     

    4,446

     

     

     

    0.02

     

    Loss on sale of asset (4)

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    268

     

     

     

    268

     

     

     

    —

     

     

     

    268

     

     

     

    —

     

    Restructuring and business transformation (5)

     

     

    200

     

     

     

    (2,393

    )

     

     

    (222

    )

     

     

    (121

    )

     

     

    2,936

     

     

     

    2,936

     

     

     

    (10

    )

     

     

    2,926

     

     

     

    0.02

     

    Adjusted (non-GAAP)

     

    $

    467,623

     

     

    $

    108,215

     

     

    $

    215,634

     

     

    $

    208,740

     

     

    $

    (64,966

    )

     

    $

    (66,696

    )

     

    $

    (1,166

    )

     

    $

    (67,862

    )

     

    $

    (0.37

    )

    Adjusted percent of revenue (non-GAAP)

     

     

    73

    %

     

     

    17

    %

     

     

    34

    %

     

     

    33

    %

     

     

     

     

     

     

     

     

     

     

    ________________

    (1) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees' contributions annually in the form of the Company's common stock.

     

    (2) Represents acquisition and related integration costs incurred as a result of the Company's business combinations. Acquisition costs represent legal and professional fees incurred to execute the transaction. There were no acquisition costs incurred for the three months ended March 31, 2025 and 2024. Integration related costs represent expenses incurred outside regular business operations, specifically relating to the integration of businesses acquired through a business combination. This includes any gain or loss on contingent consideration liabilities, severance and accelerated vesting of stock awards, and professional services. The remeasurement of the contingent consideration liabilities resulted in an expense of $8.3 million and $5.6 million for the three months ended March 31, 2025 and 2024, respectively. The Company also incurred severance costs and professional service fees which were not significant for the three months ended March 31, 2024. The majority of the professional service fees relate to the integration of information technology systems.

     

    (3) Represents impairment charges on the Company's long-lived and indefinite-lived assets. For the three months ended March 31, 2025 and 2024, the Company recorded impairment charges related to certain of our domestic facilities and corresponding leasehold improvements.

     

    (4) Relates to the sale of the intellectual property and know-how related to the Company's Oncotype DX Genomic Prostate Score test to MDxHealth SA. For the three months ended March 31, 2024, this represents the remeasurement of the associated contingent consideration.

     

    (5) In 2023 the Company began closing a domestic laboratory facility in efforts to consolidate operations. For the three months ended March 31, 2024, these expenses represent severance costs and accelerated stock-based compensation expense related to that closure. Beginning in the second half of 2024, the Company began a business transformation program intended to achieve targeted cost reductions while consolidating operations and focusing resources on its key strategic priorities. For the three months ended March 31, 2025, these costs primarily include severance costs, accelerated stock-based compensation expense, and consulting services. 

    EXACT SCIENCES CORPORATION

    U.S. GAAP to Non-GAAP Reconciliation

    Operating Cash Flow to Free Cash Flow

    (Unaudited)

    (Amounts in thousands)

     

     

     

    Three Months Ended

    March 31,

     

     

    2025

     

    2024

    Net cash provided by (used in) operating activities

     

    $

    30,809

     

     

    $

    (82,311

    )

    Net cash used in investing activities

     

     

    (34,437

    )

     

     

    (171,438

    )

    Net cash used in financing activities

     

     

    (256,171

    )

     

     

    (3,002

    )

    Effects of exchange rate changes on cash and cash equivalents

     

     

    290

     

     

     

    (1,140

    )

    Net decrease in cash, cash equivalents and restricted cash

     

     

    (259,509

    )

     

     

    (257,891

    )

    Cash, cash equivalents and restricted cash, beginning of period

     

     

    606,636

     

     

     

    609,675

     

    Cash, cash equivalents and restricted cash, end of period

     

    $

    347,127

     

     

    $

    351,784

     

     

     

     

     

     

    Reconciliation of free cash flow:

     

     

     

     

    Net cash provided by (used in) operating activities

     

    $

    30,809

     

     

    $

    (82,311

    )

    Purchases of property, plant and equipment

     

     

    (31,174

    )

     

     

    (37,649

    )

    Free cash flow

     

    $

    (365

    )

     

    $

    (119,960

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250501253431/en/

    Investor Contact:

    Derek Leckow

    Exact Sciences Corp.

    [email protected]

    608-893-0009

    Media Contact:

    Steph Spanos

    Exact Sciences Corp.

    [email protected]

    608-556-4380

    Get the next $EXAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    1/2/2024$91.00Hold → Buy
    The Benchmark Company
    12/14/2023$90.00Buy
    Guggenheim
    More analyst ratings

    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present ten abstracts at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30–June 3, 2025, in Chicago, Ill. Presentations include new data on the Oncodetect™ molecular residual disease (MRD) test, multi-cancer early detection (MCED) testing, the Oncotype DX Breast Recurrence Score® test, and the Cologuard® test that underscore Exact Sciences' expanding portfolio and commitment to advancing care through scientific excellence. "The data Exact Sciences will present at ASCO 2025 reflect the scientific rigor and clinical significance of o

      5/22/25 5:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Earns 2025 Great Place To Work® Certification™

      Award marks seventh consecutive year company has received prestigious distinction Exact Sciences (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it has been certified as a 2025 Great Place To Work® for the seventh consecutive year in the U.S., and for the first time in the U.K., Japan, Canada, France, Italy, Poland, and Germany. The recognition is based on a confidential survey of employees around the world, offering an independent assessment of Exact Sciences' culture, work environment, and leadership. This year, 77% of employees called Exact Sciences a Great Place To Work – 20 points higher than the average U.S.-based company. Great Place

      5/12/25 10:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences to Participate in May Investor Conference

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the suc

      5/2/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      11/13/24 12:56:28 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Exact Sciences Corporation

      SCHEDULE 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      5/12/25 10:32:18 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Exact Sciences Corporation

      10-Q - EXACT SCIENCES CORP (0001124140) (Filer)

      5/1/25 5:08:20 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EXACT SCIENCES CORP (0001124140) (Filer)

      5/1/25 4:06:17 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      11/13/24 2:58:53 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      11/8/24 10:52:39 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      10/7/24 11:37:08 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Exact Sciences with a new price target

      Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

      4/10/25 12:41:36 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • RBC Capital Mkts initiated coverage on Exact Sciences with a new price target

      RBC Capital Mkts initiated coverage of Exact Sciences with a rating of Sector Perform and set a new price target of $52.00

      3/13/25 7:36:02 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Exact Sciences with a new price target

      Barclays initiated coverage of Exact Sciences with a rating of Overweight and set a new price target of $70.00

      1/23/25 7:42:29 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Financials

    Live finance-specific insights

    See more
    • Exact Sciences Announces First-Quarter 2025 Results

      First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

      5/1/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Schedules First Quarter 2025 Earnings Call

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2025 financial results after the close of the U.S. financial markets on May 1, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2025 webcast & conference call details Date: Thursday, May 1, 2025 Time: 5 p.m. ET Webcast: The live webcast can be accessed at www.exactsciences.com Telephone: Domestic callers, dial 888-330-2384 International callers, dial +1 240-789-2701 Access cod

      4/1/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Exact Sciences Announces Fourth Quarter 2024 Results

      Fourth quarter and 2024 highlights Total fourth quarter revenue of $713 million, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $553 million and Precision Oncology revenue of $161 million Total 2024 revenue of $2.76 billion, an increase of 10%, or 11% on a core revenue basis, with Screening revenue of $2.10 billion and Precision Oncology revenue of $655 million Plans to launch three new cancer tests in 2025: Cologuard Plus™, next-generation colorectal cancer screening test, Oncodetect™, molecular residual disease test, and Cancerguard™, multi-cancer screening test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic

      2/19/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel & Sec Herriott James was granted 363 shares, increasing direct ownership by 2% to 15,585 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      5/8/25 4:30:09 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Director Trigg Leslie was granted 8,527 shares, increasing direct ownership by 877% to 9,499 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      5/1/25 4:31:25 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • New insider Trigg Leslie claimed ownership of 972 shares (SEC Form 3)

      3 - EXACT SCIENCES CORP (0001124140) (Issuer)

      5/1/25 4:30:04 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    Leadership Updates

    Live Leadership Updates

    See more
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology
    • Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

      Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl

      7/25/24 8:00:00 AM ET
      $EXAS
      $PODD
      Medical Specialities
      Health Care
      Medical/Dental Instruments